Circulating Exosome microRNAs as Diagnostic Biomarkers of Dementia

Dong, Xiaoyu; Zheng, Dongming; Nao, Jianfei

doi:10.3389/fnagi.2020.580199

Cited by 23 publications

(18 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Numerous studies have confirmed that exosome-derived proteins, lncRNAs or miRNAs can be stably detected in body fluids (He et al, 2018 ). These molecules have been considered as novel biomarkers for the diagnosis of neurodegenerative diseases, including AD (Dong et al, 2020 ); however, the potential diagnostic value of quantifying exosome-derived biomarkers for AD or MCI has not previously been confirmed through a systematic analysis. Thus, this meta-analysis was performed to elucidate the diagnostic value of exosome-derived biomarkers in AD or MCI.…”

Section: Discussionmentioning

confidence: 99%

The Diagnostic Value of Exosome-Derived Biomarkers in Alzheimer's Disease and Mild Cognitive Impairment: A Meta-Analysis

Xing

Gao

et al. 2021

Front. Aging Neurosci.

View full text Add to dashboard Cite

Background: Alzheimer's disease (AD) diagnoses once depended on neuropathologic examination. Now, many widely used, validated biomarkers benefits for monitoring of AD neuropathologic changes. Exosome-derived biomarker studies have reported them to be significantly related to AD's early occurrence and development, although the findings are inconclusive. The aim of this meta-analysis was to identify exosome-derived biomarkers for the diagnosis of AD and mild cognitive impairment (MCI).Methods: PubMed, PubMed Central, Web of Science, Embase, Google Scholar, Cochrane Library, the Chinese National Knowledge Infrastructure (CNKI), and the Chinese Biomedical Literature Database (CBM) were searched for studies assessing the diagnostic value of biomarkers, including data describing the pooled sensitivity (SEN), specificity (SPE), positive diagnostic likelihood ratio (DLR+), negative diagnostic likelihood ratio (DLR–), diagnostic odds ratio (DOR), and area under the curve (AUC). The quality of the included studies was assessed using RevMan 5.3 software. Publication bias was analyzed.Results: In total, 19 eligible studies, including 3,742 patients, were selected for this meta-analysis. The SEN, SPE, DLR+, DLR–, DOR, and AUC (95% confidence intervals) of exosome-derived biomarkers in the diagnosis of AD or MCI were 0.83 (0.76–0.87), 0.82 (0.77–0.86), 4.53 (3.46–5.93), 0.21 (0.15–0.29), 17.27 (11.41–26.14), and 0.89 (0.86–0.92), respectively. Sub-group analyses revealed that studies based on serum or microRNA (miRNA) analysis, and those of Caucasian populations, AD patients, patient sample size >50, neuron-derived exosomes (NDE) from plasma and p-tau had higher sensitivity, specificity, and AUC values.Conclusion: Exosome-derived biomarkers have shown potential diagnostic value in AD and MCI, although further research is required for confirmation.

show abstract

Section: Discussionmentioning

confidence: 99%

The Diagnostic Value of Exosome-Derived Biomarkers in Alzheimer's Disease and Mild Cognitive Impairment: A Meta-Analysis

Xing

Gao

et al. 2021

Front. Aging Neurosci.

View full text Add to dashboard Cite

show abstract

“…However, some inconsistent results have been reported; for instance, results suggest CSF exosomes from AD patients exhibit increased levels of miR-125b-5p, yet data from another study indicate its levels in plasma exosomes are associated with poor cognitive performance ( Rani et al, 2017 ; McKeever et al, 2018 ). As there appears to be minimal concordance across studies, the application of exosomal miRNAs as reliable diagnostic indicators may currently be limited to within particular individuals ( Dong et al, 2020 ).…”

Section: Using Exosomes To Improve Outcomes In Cognitve Declinementioning

confidence: 99%

Exosomes in Age-Related Cognitive Decline: Mechanistic Insights and Improving Outcomes

Duggan

Foster

et al. 2022

Front. Aging Neurosci.

View full text Add to dashboard Cite

Aging is the most prominent risk factor for cognitive decline, yet behavioral symptomology and underlying neurobiology can vary between individuals. Certain individuals exhibit significant age-related cognitive impairments, while others maintain intact cognitive functioning with only minimal decline. Recent developments in genomic, proteomic, and functional imaging approaches have provided insights into the molecular and cellular substrates of cognitive decline in age-related neuropathologies. Despite the emergence of novel tools, accurately and reliably predicting longitudinal cognitive trajectories and improving functional outcomes for the elderly remains a major challenge. One promising approach has been the use of exosomes, a subgroup of extracellular vesicles that regulate intercellular communication and are easily accessible compared to other approaches. In the current review, we highlight recent findings which illustrate how the analysis of exosomes can improve our understanding of the underlying neurobiological mechanisms that contribute to cognitive variation in aging. Specifically, we focus on exosome-mediated regulation of miRNAs, neuroinflammation, and aggregate-prone proteins. In addition, we discuss how exosomes might be used to enhance individual patient outcomes by serving as reliable biomarkers of cognitive decline and as nanocarriers to deliver therapeutic agents to the brain in neurodegenerative conditions.

show abstract

“…AD differential diagnosis. For a comprehensive review of circulating exosomes’ miRNAs differently expressed in dementias and useful in differential diagnosis see [ 143 ].…”

Section: Mirna Expression Profilingmentioning

confidence: 99%

Genetic Architecture and Molecular, Imaging and Prodromic Markers in Dementia with Lewy Bodies: State of the Art, Opportunities and Challenges

Combi

Salsone

Clara

et al. 2021

IJMS

View full text Add to dashboard Cite

Dementia with Lewy bodies (DLB) is one of the most common causes of dementia and belongs to the group of α-synucleinopathies. Due to its clinical overlap with other neurodegenerative disorders and its high clinical heterogeneity, the clinical differential diagnosis of DLB from other similar disorders is often difficult and it is frequently underdiagnosed. Moreover, its genetic etiology has been studied only recently due to the unavailability of large cohorts with a certain diagnosis and shows genetic heterogeneity with a rare contribution of pathogenic mutations and relatively common risk factors. The rapid increase in the reported cases of DLB highlights the need for an easy, efficient and accurate diagnosis of the disease in its initial stages in order to halt or delay the progression. The currently used diagnostic methods proposed by the International DLB consortium rely on a list of criteria that comprises both clinical observations and the use of biomarkers. Herein, we summarize the up-to-now reported knowledge on the genetic architecture of DLB and discuss the use of prodromal biomarkers as well as recent promising candidates from alternative body fluids and new imaging techniques.

show abstract

Circulating Exosome microRNAs as Diagnostic Biomarkers of Dementia

Cited by 23 publications

References 91 publications

The Diagnostic Value of Exosome-Derived Biomarkers in Alzheimer's Disease and Mild Cognitive Impairment: A Meta-Analysis

The Diagnostic Value of Exosome-Derived Biomarkers in Alzheimer's Disease and Mild Cognitive Impairment: A Meta-Analysis

Exosomes in Age-Related Cognitive Decline: Mechanistic Insights and Improving Outcomes

Genetic Architecture and Molecular, Imaging and Prodromic Markers in Dementia with Lewy Bodies: State of the Art, Opportunities and Challenges

Contact Info

Product

Resources

About